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The objective of this study was to evaluate the usefulness of comprehensive chromosome screening (CCS) using array comparative
genomic hybridization (aCGH). The study included 1420 CCS cycles for recurrent miscarriage (𝑛 = 203); repetitive implantation
failure (𝑛 = 188); severe male factor (𝑛 = 116); previous trisomic pregnancy (𝑛 = 33); and advanced maternal age (𝑛 = 880).
CCS was performed in cycles with fresh oocytes and embryos (𝑛 = 774); mixed cycles with fresh and vitrified oocytes (𝑛 = 320);
mixed cycles with fresh and vitrified day-2 embryos (𝑛 = 235); and mixed cycles with fresh and vitrified day-3 embryos (𝑛 = 91).
Day-3 embryo biopsy was performed and analyzed by aCGH followed by day-5 embryo transfer. Consistent implantation (range:
40.5–54.2%) and pregnancy rates per transfer (range: 46.0–62.9%) were obtained for all the indications and independently of the
origin of the oocytes or embryos. However, a lower delivery rate per cycle was achieved in women aged over 40 years (18.1%) due
to the higher percentage of aneuploid embryos (85.3%) and lower number of cycles with at least one euploid embryo available per
transfer (40.3%). We concluded that aneuploidy is one of the major factors which affect embryo implantation.
1. Introduction
Aneuploidies are common in early human embryos [1, 2].
Trisomic andmonosomic embryos account for at least 10% of
human pregnancies and, for women nearing the end of their
reproductive lifespan, the incidence may exceed 50% [3].
Further, aneuploidy rates are higher in oocytes and embryos
from women with advanced maternal age (AMA) [4] which
probably stems from meiotic recombination defects exac-
erbated by age [5]. Recent studies in humans and model
organisms have shed new light on the complexity of meiotic
defects, providing evidence that the age-related increase in
errors in human females is not attributable to a single factor
but to an interplay between the unique features of oogenesis
and a host of other endogenous and exogenous factors
[3]. Age-related defects result in higher aneuploidy rates in
offspring and an increase in spontaneous abortions, thereby
reducing ongoing implantation rates [6]. Aneuploidy may
also be a contributing factor in other infertile populations;
for example, despite other potential causes, an abnormal
embryonic karyotype was found to be the most frequent
cause of recurrent miscarriage (RM) [7]. In the same study,
the percentage of cases with RM of truly unexplained origin
was limited to 24.5%. While the diagnosis of repetitive
implantation failure (RIF) remains a clinical challenge (its
causes can be multiple, often with ill-defined embryonic
and endometrial contributing factors), embryonic aneu-
ploidy has been proposed as one of the leading embryonic
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causes [8]. In male factor (MF) infertility, an increase in
sperm chromosomal abnormalities due to impairment of
the meiotic process has been described [9, 10]. Addition-
ally, a higher incidence of abnormal karyotypes has been
described in the miscarriages of couples undergoing intra-
cytoplasmic sperm injection (ICSI) because of MF infertility
[11].
Despite a meta-analysis compiling nine randomized con-
trolled clinical trials (RCTs) [12] indicating that there is no
benefit to preimplantation genetic screening (PGS) by fluo-
rescence in situ hybridization (FISH) for a limited number
of chromosomes, some controversial opinions have surfaced
regarding the convenience for embryo aneuploidy screening
[13–19], including our own experience which differs from
previously published studies. We conducted two prospective,
randomized trials to evaluate the usefulness of PGS in AMA
patients between 41 and 44 years of age and RIF patients
aged less than 40 years of age. We observed a significant
increase in the live birth rates in the PGS group compared to
the blastocyst group in the AMA study (32.3% versus 15.5%;
𝑃 = 0.0099) and a clear trend towards increased live birth
rates in the RIF study (47.9% versus 27.9%). We therefore
concluded that PGS with classic FISH is beneficial for these
two indications if proper blastomere biopsy procedures and
good laboratory conditions are applied [20].
Despite our findings, there is still a clear need for a
technique capable of comprehensive chromosome screening
(CCS), which could also produce reliable and faithful results
in a short period of time.The first approach was comparative
genomic hybridization (CGH), and several studies were
published using this technology [21–23]. However, in the last
three years, embryo aneuploidy screening has evolved: it is
more broadly applied in in vitro fertilization (IVF) programs
and now includes other approaches that allow results to be
obtained in a shorter period of time, such as oligoarrays,
single nucleotide polymorphism arrays, quantitative PCR,
andCGHbacterial artificial chromosome arrays (SNP, qPCR,
and CGH BAC, resp.) [24–33]. In two recently published
reviews, array-CGH (aCGH) was described as a robust and
accessible diagnostic approach to assess 24-chromosome
aneuploidy, and hence IVF programs are moving towards
PGS using aCGH [34, 35].
Independent of the type of platform used, the technique
selected for screening all 24 chromosomes should offer reli-
able and timely results and should only be applied in clinical
programs after validation with an already well-established
technique. In our program, we first validated the aCGH
platform in single cells from embryos previously diagnosed as
abnormal by FISH, obtaining similar error rates below three
percent for both techniques [36]. Next, we confirmed that
there were no differences in efficiency and accuracy when
comparing day-3 and day-5 whole embryo array analysis
[30]. This was further validated in another study using the
same aCGH platform confirming the high efficiency of the
platform: only 2.9% of embryos had no results, and the error
rate when compared to FISH was 1.9% [37]. In the work
presented here, we describe our current experience with the
clinical application of CCS using aCGH for different clinical
indications, considering oocyte and embryo vitrification as a
coadjuvant technique to improve reproductive outcomes in
IVF patients.
2. Materials and Methods
2.1. Patients. This retrospective study compiled 1420 cycles
with a day-3 biopsy in which aCGH analysis was performed,
from February 2010 to February 2013. Clinical indications for
CCS were the following: RM (two or more miscarriages of
unknown etiology); RIF (three or more previous IVF fail-
ures); MF (low sperm concentration or a significant increase
in sperm chromosomal abnormalities); couples with a previ-
ous trisomic pregnancy (PTP); and AMA (40 years or older).
The study included different cycle types: cycles in which
all oocytes and embryos came from fresh cycles (𝑛 = 774);
mixed cycleswith fresh and vitrified oocytes (𝑛 = 320);mixed
cycles with fresh and vitrified day-2 embryos (𝑛 = 235); and
mixed cycles with fresh and vitrified day-3 embryos (𝑛 = 91).
The goal of vitrification at different stages was to increase the
number of embryos for the analysis within a single CCS cycle.
2.2. Embryo Biopsy and Culture Conditions. Patients under-
went ovarian stimulation using standardized protocols.
When at least two follicles reached 18mm in diameter,
recombinant human chorionic gonadotropin (hCG, Ovit-
relle, 250mg, Merck Serono, Geneva, Switzerland) was
administered, and oocyte retrieval was scheduled 36 hours
later. ICSI was performed in all cases [38]. Fertilization
was assessed 17–20 hours after microinjection, and embryo
cleavage was recorded every 24 hours. The CCS cycles were
performed in different IVF centers using twomain protocols.
In most centers, embryos were grown in IVF/CCM medium
(1/1) (Vitrolife, Go¨teborg, Sweden) until day 3 and were
subsequently cultured in CCMmedium with a monolayer of
endometrial epithelial cells until day 5 [39]. In the remaining
centers, global sequential culture system (LifeGlobal, Guil-
ford, CT) was used with tri-gas incubators (7% O
2
and 5%
CO
2
).
Embryo biopsy was performed on day 3 and can
be summarized as follows: embryos were placed on a
droplet containing Ca2+/Mg2+-free medium (G-PGD, Vitro-
life, Go¨teborg, Sweden/LifeGlobal, Guilford, CT), the zona
pellucida was perforated using laser technology (OCTAX,
Herborn, Germany), and one blastomere was withdrawn
from each embryo. Only embryos with five ormore nucleated
blastomeres and less than 25% fragmentation were biopsied.
Individual blastomeres were placed in 0.2mL PCR tubes
containing 2 𝜇L PBS. For blastomere washing and handling,
1% polyvinylpyrrolidone (PVP) was used. Properly devel-
oped euploid embryos were transferred on day 5, and surplus
euploid embryos were vitrified either on day 5 or on day 6.
2.3. Oocyte and Embryo Vitrification. The Cryotop method
was used as previously described by Kuwayama et al.
(2005) [40] and adapted for our laboratory [41]. In brief,
oocytes/embryos were immersed in a solution containing
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7.5% (v/v) ethylene glycol (EG) with 7.5% (v/v) dimethylsul-
foxide (DMSO) in TCM199mediumwith 20% (v/v) synthetic
serum substitute (SSS) at room temperature for 15 minutes.
Subsequently, oocytes/embryos were placed in a solution
containing 15% EG with 15% DMSO and 0.5mol/L sucrose.
One minute later, they were placed on the Cryotop strip and
immediately submerged in filtered liquid nitrogen (Brymill
filter model 9409, Brymill Corporation, Ellington, CT, USA).
For warming, the Cryotop was removed from the liquid
nitrogen and instantly placed in 1.0M sucrose in TCM199
with 20% SSS at 37∘C. After 1 minute, oocytes/embryos were
placed in 0.5mol/L sucrose in TCM199 with 20% SSS at room
temperature for 3 minutes. Finally, two consecutive washes
(5 minutes and 1 minute) were performed with TCM199 with
20% SSS at room temperature before oocytes were incubated
at 37∘C for two hours preceding ICSI.
2.4. DNA Amplification and Array-Comparative Genomic
Hybridization Protocol. To perform day-3 aCGH analysis, a
single cell fromeach embryowas amplified using the Sureplex
DNA amplification system (BlueGnome, Cambridge, UK).
Amplification quality was ensured by gel electrophoresis
(Lonza, Rockland, USA). Sample and control DNA were
labelled with Cy3 and Cy5 fluorophores following the man-
ufacturer’s instructions. Labelling mixes were combined
and hybridized on 24sure arrays (V2 and V3, BlueGnome,
Cambridge, UK) for 6–12 hours. Each probe is specific to
a different chromosomal region and occupies a discrete
spot on the slide. Chromosomal loss or gain is revealed
by the color adopted by each spot after hybridization. The
technique involves the competitive hybridization of differen-
tially labeled test and reference DNA samples. Fluorescence
intensity was detected using a laser scanner (Powerscanner,
TECAN, Ma¨nnedorf, Switzerland), and BlueFuse Multi soft-
ware was used for data processing (BlueGnome, Cambridge,
UK). The “24sure microarray product description (February
8, 2012, document version 2.3, and model number 408501-
00)” describes 10Mb effective resolution for 24sure using
BlueFuse software, being this the minimum size specified by
BlueGnome for segmental aneuploidies. The entire protocol
can be completed in less than 24 hours and, therefore, embryo
transfer and vitrification of surplus euploid embryos can be
scheduled for day 5.
2.5. Statistics. The chi-square test and Fisher exact test were
used for comparisons between study groups with respect
to percentages. Welch 𝑡-test was used to compare noncate-
gorical variables. Bonferroni’s correction for multiple group
comparisons was applied and 𝑃 < 0.05 was considered
statistically significant. The implantation rate was defined
as the percentage of embryos transferred resulting in an
implanted gestational sac. The pregnancy rate per transfer
was calculated as the percentage of clinical pregnancies with
a fetal heart beat. The miscarriage rate was defined as the
percentage of clinical pregnancies that were spontaneously
miscarried before week 12 of pregnancy.The delivery rate per
cycle was defined as the number of cycles with a live birth.
3. Results and Discussion
3.1. General Clinical Results. A total of 1420 CCS cycles were
performed. The mean female age was 39.4 (SD 3.4). A total
of 7210 embryos were analyzed and, in 7118 (98.7%) of them,
amplification and further analysis were successful. A high
percentage of aneuploid embryos were observed for all 24
chromosomes (77.6%), with 3.9% of them showing segmental
aneuploidies defined as gains or losses of chromosome
fragments with size larger than 10Mb. A chaotic pattern was
observed in 15.0% of the embryos. In 783 cycles, at least one
euploid embryo was available for transfer, with a pregnancy
rate of 53.4% per transfer and 29.4% per cycle. The miscar-
riage rate was 7.4%, and the delivery rate per cycle was 27.3%.
The results from our CCS program using aCGH technology
support our previous experience of the benefits of using FISH
for a limited number of chromosomes. In fact, the average
pregnancy rate per transfer for all indications was higher
than in our previously published studies using FISH for
similar indications, which produced pregnancy rates ranging
between 30 and 40% [42–44].Therefore, the incorporation of
aCGH in our aneuploidy screening program has resulted in a
clear increase in pregnancy and implantation rates, showing
that aneuploidies for any of the 24 chromosomes can appear
in preimplantation embryos and therefore can impair embryo
viability and implantation.
3.2. Clinical Results according to the Origin of Oocytes and
Embryos. Table 1 summarizes our results according to the
origin of oocytes and embryos. Comparisons among the
four groups showed a similar mean female age. The mean
number of MII oocytes was 9.0 (SD 4.9) in the group of
fresh oocytes; 10.1 (SD 4.7) in the vitrified oocytes group;
12.4 (SD 6.6) in the group of day-2 vitrified oocytes, and 12.8
(SD 6.9) in the day-3 vitrified embryo group.The informative
and aneuploid embryos as well as their clinical outcomes
were similar among groups, showing that vitrification had
no detrimental clinical impact at any stage compared to
fresh cycles. Statistical differences were only observed in the
mean number of embryos analyzed (which was significantly
higher for vitrified oocyte and vitrified day-2 embryo groups
compared to fresh and day-3 vitrified cycle groups) and in
the percentage of cycles reaching the embryo transfer stage,
which was lower for vitrified oocytes compared to day-2
vitrified cycle groups.
A high proportion of cycles (62%) were performed in
women who were aged 40 years or more. For this reason, in
women with low ovarian response, the goal of vitrification
was to accumulate a sufficient number of MII oocytes or
embryos to be able to achieve embryo transfer and subse-
quent ongoing pregnancy. Oocyte vitrification from different
stimulation cycles for oocyte accumulation has been success-
fully applied to low-responder patients in regular IVF cycles
[45] and the introduction of vitrification in IVF programs
opens new possibilities for embryo selection and CCS [46,
47]. Additionally, another recent publication showed that the
process of oocyte vitrification does not increase embryonic
aneuploidy and does not impact implantation [48]. An
alternative for achieving an optimal number of embryos for
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biopsy is vitrification at the cleavage stage, which has also
shown optimal performance in a long retrospective study
[49]. However, a recent study of aCGH cycles showed that the
cohort size was not significantly associated with the euploidy
rate [50]. In this present study, the group of mixed vitrified
oocytes showed the highest percentage of embryos withmore
than one aneuploidy (36.9%), which may be due to the older
age of thewomen included in this group. Embryo vitrification
at any of the other stages before the biopsy did not have an
impact on the percentage and distribution of different types
of chromosomal abnormalities. Similar aneuploidy rates were
obtained in fresh cycles (77.2%) compared to mixed cycles
with vitrified oocytes (79.7%), day-2 (76.8%), or day-3 (77.1%)
cleavage-stage embryos; no differences were observed in
pregnancy, implantation, or delivery rates. These data are
comparable to those recently published regarding cycles with
fresh and vitrified oocytes from our ovumdonation program.
Similar metabolomic profiles were also observed in embryos
derived from fresh and vitrified oocytes, supporting the
feasibility of accumulating oocytes or embryos for a single
CCS cycle analysis [51].
3.3. Clinical Results according to the Comprehensive Chromo-
some Screening Indication. Table 2 shows the results for the
different infertility indications studied. The mean number
of embryos analyzed was significantly higher for the MF
indication compared to the other indications, with a lower
number of embryos analyzed for the AMA group (mean
4.6). The percentage of aneuploid embryos was similar for all
indications below 40 years of age, with a significant increase
in the AMA group (85.3%) compared to all the other groups
(68.2% in RM, 67.7% in RIF, 71.5% in PTP, and 65.4% in
MF). These results had an impact in the percentage of cycles
with at least one euploid embryo for transfer, making it
significantly lower for the AMA group (40.3%) compared to
all the other indications (77.3% in RM, 79.2% in RIF, 78.8% in
PTP, and 83.6% in MF). However, once embryo transfer was
achieved, the chances of successful pregnancy and implan-
tation were similar for all the mentioned indications, with
a range between 46.0% and 62.9% for pregnancy rates per
transfer and between 40.5% and 54.2% for implantation rates.
However, the pregnancy rate per CCS cycle was significantly
lower for the AMA group (19.3%) compared to the remaining
indications (44.3%, 45.2%, 36.4%, and 52.1% for RM, RIF,
PTP, and MF, resp.) due to the previously mentioned high
transfer-cancellation rate.The delivery rate per cycle was also
significantly lower for the AMA group (18.1%) compared to
the other indications (38.4% in RM, 43.1% in RIF, 30.3% in
PTP, and 50.9% in MF).
Despite the minimal effect of maternal age on implan-
tation after the transfer of a euploid embryo, a negative
effect on delivery rates has been described by other authors.
A retrospective case-controlled study including CCS cycles
with aCGH for PGS in AMA, RM, and RIF patients reported
lower ongoing pregnancy rates per cycle in patients 35 years
or older compared to patients less than 35 years. However,
even in cycles in patients 38 years or older, the implantation,
clinical pregnancy, and ongoing pregnancy rates significantly
increased after CCS in these groups compared to their con-
trols [52]. Another multicenter retrospective study described
an increase in the incidence of aneuploid embryos, which
correlated with increased maternal age, observing similar
implantation and ongoing pregnancy rates per transfer after
CCS in patients up to 42 years of age, after which these rates
dramatically declined [53].
Interestingly, Table 2 shows a different distribution of
chromosomal abnormality types according to the indica-
tion. The highest incidence of segmental aneuploidies was
observed in couples with a previous chromosomally abnor-
mal pregnancy (10.2%) and the lowest was in the AMA
group (3.2%). The distribution of embryos showing a chaotic
pattern was relatively homogenous among indications, with
a slight decrease in RIF patients (11.2%) compared to RM
(16.4%) and AMA (15.6%) patients. The most remarkable
difference was observed for the percentage of embryos with
aneuploidy for more than one chromosome, which was
significantly higher in the AMA group (43.1%) compared to
all other indications (range: 19.8%–23.5%). This percentage
increases with maternal age, reaching values from 32.8%
in 40 years to 65.8% in 46 years of age. Therefore, the
overall incidence of aneuploidy ranges from 79.0% to 95.7%
(Figure 1). This relationship between maternal age and the
complexity of aneuploid errors has recently been described
by Franasiak et al. (2013) [54] in a systematic report of 15169
CCS results, showing that 36% of embryos had more than
one aneuploidy and that the proportion of more complex
aneuploidy increases with age.
In RM couples, the transfer of euploid embryos after
CCS results in a low miscarriage rate (13.3%). A multicenter
study of 287 cycles in couples with idiopathic RM described
60% of the embryos as aneuploid but with a miscarriage rate
of 6.9% after CCS, compared to the expected rate of 33.5%
in RM control population and 23.7% in an infertile control
population [28]. These results showed a clear benefit of 24-
chromosome screening in couples with this etiology.
In RIF couples, previous RCTs using FISH for a limited
number of chromosomes showed controversial results, with
one study showing no clear benefit [55] and another showing
an improvement in live birth rates compared to blastocyst
transfer without previous FISH analysis [20]. Despite this,
there is no RCT regarding CCS with aCGH for RIF patients,
although the results described in our study support the
application of aneuploidy screening for this group of patients.
In PTP couples, published data describe an increased risk
of recurrent aneuploid conceptions, particularly in women
under 37 years of age [56]. Previous studies on PGS with
FISH analysis of a 9-chromosome panel showed high rates
of abnormal embryos, ranging from 48.1% to 71.2% [57, 58],
which is in agreement with the percentage of 71.5% observed
in our study with 24-chromosome analysis.
Finally, we found the best clinical results after CCS inMF
couples. Although, to our knowledge, there are no publica-
tions regarding CCS in MF infertile couples, this type of 24-
chromosome CCS seems to be a very promising indication
for this patient group, as also suggested by previous similar
publications with PGS using FISH analysis [42, 59].
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Figure 1: Aneuploidy rates according to maternal age in AMA group.
4. Conclusions
Our findings on day-3 embryo biopsies support the basis for
CCS in patients in whom a high proportion of aneuploid
embryos are suspected. New RCTs should be conducted in
the near future to assess the feasibility of using different
platforms for different clinical indications and to test for any
potential increases in live birth rates resulting from more
comprehensive aneuploidy screening before embryo transfer.
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